BRPI0309534B8 - derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica - Google Patents

derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica

Info

Publication number
BRPI0309534B8
BRPI0309534B8 BRPI0309534A BR0309534A BRPI0309534B8 BR PI0309534 B8 BRPI0309534 B8 BR PI0309534B8 BR PI0309534 A BRPI0309534 A BR PI0309534A BR 0309534 A BR0309534 A BR 0309534A BR PI0309534 B8 BRPI0309534 B8 BR PI0309534B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
receptor antagonists
compound
triazole derivatives
tachykinin receptor
Prior art date
Application number
BRPI0309534A
Other languages
English (en)
Other versions
BR0309534A (pt
BRPI0309534B1 (pt
Inventor
Kudzovi Amegadzie Albert
Stephen Muehl Brian
Michael Remick David
James Hembre Erik
Eric Hong Jian
Allen Savin Kenneth
Matthew Gardinier Kevin
Nickolaus Jungheim Louis
Alan Robertson Michael
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0309534A publication Critical patent/BR0309534A/pt
Publication of BRPI0309534B1 publication Critical patent/BRPI0309534B1/pt
Publication of BRPI0309534B8 publication Critical patent/BRPI0309534B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"composto, composição farmacêutica, e, uso de um composto". este relatório descritivo refere-se a um composto de fórmula ou um sal farmaceuticamente aceitável do mesmo, a composições farmacêuticas do mesmo, e a seu uso como inibidor do subtipo nk-1 de receptores de taquiquinina, e também a um processo para sua preparação, e intermediários para os mesmos. (1) em que: d é uma anel alcano c~ 1~-c~ 3~; r^ 1^ é fenila, que é opcionalmente substituído por de um a três substituintes selecionados independentemente do grupo que consiste de halo, alquila c~ 1~-c~ 4~, alcóxi c~ 1~-c~ 4~, ciano, difluorometila, trifluorometila, e trifluorometóxi: r^ 4^ é um radical selecionado do grupo que consiste de: (ia), (ib), (ic), (id), (ie), (if), (ig), (ih)
BRPI0309534A 2002-04-26 2003-04-22 derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica BRPI0309534B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37612102P 2002-04-26 2002-04-26
US60/376,121 2002-04-26
PCT/US2003/010681 WO2003091226A1 (en) 2002-04-26 2003-04-22 Triazole derivatives as tachykinin receptor antagonists

Publications (3)

Publication Number Publication Date
BR0309534A BR0309534A (pt) 2005-02-01
BRPI0309534B1 BRPI0309534B1 (pt) 2017-11-07
BRPI0309534B8 true BRPI0309534B8 (pt) 2021-05-25

Family

ID=29270766

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309534A BRPI0309534B8 (pt) 2002-04-26 2003-04-22 derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica

Country Status (31)

Country Link
US (1) US7320994B2 (pt)
EP (1) EP1501809B1 (pt)
JP (1) JP4559087B2 (pt)
KR (1) KR100755577B1 (pt)
CN (1) CN1312136C (pt)
AR (1) AR039329A1 (pt)
AT (1) ATE384053T1 (pt)
AU (1) AU2003230829B8 (pt)
BR (1) BRPI0309534B8 (pt)
CA (1) CA2483159C (pt)
CR (1) CR7548A (pt)
CY (1) CY1107221T1 (pt)
DE (1) DE60318697T2 (pt)
DK (1) DK1501809T3 (pt)
EA (1) EA007720B1 (pt)
EC (1) ECSP045391A (pt)
ES (1) ES2298513T3 (pt)
HK (1) HK1073304A1 (pt)
HR (1) HRP20041008B1 (pt)
IL (2) IL164675A0 (pt)
MX (1) MXPA04010622A (pt)
MY (1) MY141559A (pt)
NO (1) NO333647B1 (pt)
NZ (1) NZ535886A (pt)
PE (1) PE20040600A1 (pt)
PL (1) PL212090B1 (pt)
PT (1) PT1501809E (pt)
TW (1) TWI265807B (pt)
UA (1) UA79113C2 (pt)
WO (1) WO2003091226A1 (pt)
ZA (1) ZA200408670B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638944A1 (en) * 2003-06-12 2006-03-29 Eli Lilly And Company Tachykinin receptor antagonists
ATE462700T1 (de) * 2003-10-24 2010-04-15 Lilly Co Eli Neue kristalline formen von ä2-ä1-(3,5- bistrifluormethylbenzyl)-5-pyridin-4-yl-1h-ä1,2 3üütriazol-4-ylü-pyridin-3-ylü-(2- chlorphenyl)methanon
WO2006083711A1 (en) * 2005-02-01 2006-08-10 Eli Lilly And Company Tachykinin receptor antagonists
WO2006106711A1 (ja) 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
EP1894919B1 (en) * 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
MX2008000781A (es) * 2005-07-25 2008-03-10 Hoffmann La Roche Derivados de triazol substituidos y su uso como antagonistas del receptor neuroquinina 3.
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
MX2009001710A (es) * 2006-08-18 2009-02-25 Syngenta Ltd Uso de inhibidores hppd para el tratamiento de la depresion y/o sindrome de abstinencia asociados con drogas adictivas.
WO2008035726A1 (fr) 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
US8772496B2 (en) * 2006-12-20 2014-07-08 Eli Lilly And Company Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CA2695812A1 (en) * 2007-08-08 2009-02-12 Neurosearch A/S Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
AU2009263037B2 (en) * 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
GB0823002D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isoxazoles derivatives with plant growth regulating properties
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
DK3265087T3 (da) * 2015-03-04 2020-10-19 Vanda Pharmaceuticals Inc Fremgangsmåde til behandling med tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
PL3464271T3 (pl) 2016-05-31 2021-01-25 Kalvista Pharmaceuticals Limited Pochodne pirazolowe jako inhibitory kalikreiny osoczowej
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
EP3681505A1 (en) 2017-09-13 2020-07-22 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
CN111343981A (zh) 2017-11-17 2020-06-26 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
HRP20220367T1 (hr) 2017-11-29 2022-05-27 Kalvista Pharmaceuticals Limited Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
JP7410137B2 (ja) * 2018-06-08 2024-01-09 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントを用いる処置方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
AU2019348001B2 (en) * 2018-09-28 2023-09-21 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US20220096449A1 (en) 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
JP2023515167A (ja) 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
JP2023519570A (ja) 2020-04-03 2023-05-11 ネッレ セラピューティクス リミテッド 新規使用
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
CN115697332A (zh) 2020-06-02 2023-02-03 尼尔医疗有限公司 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂
CN111662235B (zh) * 2020-06-23 2023-12-22 黄淮学院 一种苯甲酰基哒嗪衍生物及其制备方法
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
WO2023034718A1 (en) 2021-08-31 2023-03-09 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
WO1995011880A1 (en) * 1993-10-27 1995-05-04 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
AU2633897A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles
EA006626B1 (ru) 1996-07-24 2006-02-24 Дюпон Фармасьютикалз Компани Азолопиримидины, фармацевтическая композиция и способ лечения
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
WO1999007677A1 (en) 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
ATE318259T1 (de) * 1999-12-17 2006-03-15 Schering Corp Selektive neurokinin-antagonisten
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
JP2002123925A (ja) 2000-10-13 2002-04-26 Fuji Photo Film Co Ltd 磁気記録媒体
ATE399770T1 (de) * 2002-04-26 2008-07-15 Lilly Co Eli Tachykininrezeptorantagonisten

Also Published As

Publication number Publication date
BR0309534A (pt) 2005-02-01
CN1312136C (zh) 2007-04-25
US20050239786A1 (en) 2005-10-27
TW200306824A (en) 2003-12-01
EP1501809B1 (en) 2008-01-16
PL212090B1 (pl) 2012-08-31
JP2005536458A (ja) 2005-12-02
HRP20041008B1 (hr) 2012-10-31
MY141559A (en) 2010-05-14
KR20040104634A (ko) 2004-12-10
NO20045120L (no) 2004-12-07
EA200401431A1 (ru) 2005-06-30
AR039329A1 (es) 2005-02-16
DE60318697D1 (de) 2008-03-06
HK1073304A1 (en) 2005-09-30
DK1501809T3 (da) 2008-05-13
CA2483159C (en) 2010-08-10
NZ535886A (en) 2007-07-27
AU2003230829B8 (en) 2008-12-11
AU2003230829B2 (en) 2008-12-04
PT1501809E (pt) 2008-03-18
IL198122A0 (en) 2009-12-24
US7320994B2 (en) 2008-01-22
PL373504A1 (en) 2005-09-05
EP1501809A1 (en) 2005-02-02
ECSP045391A (es) 2005-01-03
AU2003230829A1 (en) 2003-11-10
BRPI0309534B1 (pt) 2017-11-07
IL164675A0 (en) 2005-12-18
HRP20041008A2 (en) 2004-12-31
JP4559087B2 (ja) 2010-10-06
CA2483159A1 (en) 2003-11-06
MXPA04010622A (es) 2005-01-25
CN1646502A (zh) 2005-07-27
CR7548A (es) 2006-12-01
WO2003091226A1 (en) 2003-11-06
UA79113C2 (en) 2007-05-25
EA007720B1 (ru) 2006-12-29
TWI265807B (en) 2006-11-11
ATE384053T1 (de) 2008-02-15
ES2298513T3 (es) 2008-05-16
KR100755577B1 (ko) 2007-09-12
PE20040600A1 (es) 2004-09-15
NO333647B1 (no) 2013-07-29
CY1107221T1 (el) 2012-11-21
ZA200408670B (en) 2005-10-26
DE60318697T2 (de) 2009-01-08

Similar Documents

Publication Publication Date Title
BRPI0309534B8 (pt) derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
BR0213790A (pt) Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta
RS50378B (sr) N-heterociklični derivati kao nos inhibitori
BR112013009935B8 (pt) Compostos
NO986055D0 (no) Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR0214455A (pt) Derivados benzotiazol
BRPI0810929B8 (pt) uso de um composto de fórmula 1
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
NO20051051L (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler
RS53627B1 (en) N- (3-Amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
EA200300453A1 (ru) Производные 3-ароилиндола и их применение в качестве агонистов рецепторов cb2
TW200640916A (en) (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
BRPI9913542B8 (pt) derivados de dihidrobenzodioxina carboxamida e dihidrobenzodioxina cetona como antagonistas do receptor 5-ht4 bem como composição farmacêutica, processo para a preparação dos referidos derivados e uso dos mesmos
WO2008002596A3 (en) Adenosine a2a receptor antagonists
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0510397A (pt) compostos, composições farmacêuticas contendo os mesmos, e métodos de uso dos mesmos
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
WO2008155588A8 (en) Sulfonyl-quinoline derivatives

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 249/06, C07D 401/04, C07D 4010/14, C07D 403/04, C07D 403/14, C07D 413/04, C07D C07D 417/14, C07D 487/04, C07D 498/04, A61K 31/492, A61K 31/4196, A61K 31/422, A61K 31/4439, A61K 31/427, A61K 31/497, A61K 31/501, A61K 31/05, A61P 25/00

Ipc: C07D 249/06 (2011.01), C07D 401/04 (2011.01), C07D

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/11/2017, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22/04/2023